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Abstract
The role of plasmacytoid dendritic cells (pDC) in human immunodeficiency virus type 1 (HIV-1) infection and pathogenesis
remains unclear. HIV-1 infection in the humanized mouse model leads to persistent HIV-1 infection and immunopatho-
genesis, including type I interferons (IFN-I) induction, immune-activation and depletion of human leukocytes, including CD4
T cells. We developed a monoclonal antibody that specifically depletes human pDC in all lymphoid organs in humanized
mice. When pDC were depleted prior to HIV-1 infection, the induction of IFN-I and interferon-stimulated genes (ISGs) were
abolished during acute HIV-1 infection with either a highly pathogenic CCR5/CXCR4-dual tropic HIV-1 or a standard CCR5-
tropic HIV-1 isolate. Consistent with the anti-viral role of IFN-I, HIV-1 replication was significantly up-regulated in pDC-
depleted mice. Interestingly, the cell death induced by the highly pathogenic HIV-1 isolate was severely reduced in pDC-
depleted mice. During chronic HIV-1 infection, depletion of pDC also severely reduced the induction of IFN-I and ISGs,
associated with elevated HIV-1 replication. Surprisingly, HIV-1 induced depletion of human immune cells including T cells in
lymphoid organs, but not the blood, was reduced in spite of the increased viral replication. The increased cell number in
lymphoid organs was associated with a reduced level of HIV-induced cell death in human leukocytes including CD4 T cells.
We conclude that pDC play opposing roles in suppressing HIV-1 replication and in promoting HIV-1 induced
immunopathogenesis. These findings suggest that pDC-depletion and IFN-I blockade will provide novel strategies for
treating those HIV-1 immune non-responsive patients with persistent immune activation despite effective anti-retrovirus
treatment.
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Introduction
Chronic immune activation induced by HIV-1 infection is
highly correlated with CD4 T cell depletion and immunodefi-
ciency [1,2,3]. The level of T cell activation (HLA-
DR+CD38+CD8+ T cells) is correlated with disease progression
independent of HIV-1 viral load and CD4+ T cell count [4]. It is
also proposed that immune activation drives AIDS development in
simian immunodeficiency virus (SIV) infected monkeys. In SIV-
infected Asian monkeys (Rhesus macaques and pigtail macaques,
e.g.) AIDS develops, associated with persistent immune activation
and rapid CD4+ T-cell loss. In contrast, SIV infection of African
monkeys (African Green monkeys and sooty mangabeys, e.g.) leads
to no AIDS progression, correlated with only a transient and self-
limiting immune activation despite similar levels of viral replica-
tion as pathogenic SIV infections [2,5,6]. In mice, repeated
treatments with Toll like receptor (TLR)-9 [7] or TLR7 [8] ligands
lead to AIDS-like immune dysregulation, correlated with immune
activation and lymphoid organ destruction. In SIV-infected
African green monkeys, treatment with lipopolysaccharide (LPS)
results in CD4+ T-cell loss [9]. Finally, anti-inflammatory
treatment with chloroquine [10] or hydroxychloroquine in
combination with antivirals [11] inhibits immune activation in
HIV-1 infected patients, correlated with elevated CD4+ T cells
[11].
The mechanism by which HIV-1 infection leads to immune
activation is not fully elucidated [2]. Several mechanisms have
been proposed, including loss of gut tissue integrity and microbial
products translocation [12] or persistent production of IFN-I
[13,14]. Sustained IFN-I production is correlated with HIV-1
induced immune activation and disease progression both in HIV-1
infected patients [15] and pathogenic SIV infected monkey models
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[16,17,18]. Although IFN-I inhibits HIV-1 replication in vitro
[19], the high level IFN-I in HIV-1 patients is not correlated with
viral control but is predictive of HIV-1 disease progression [20,21].
IFN-I is induced during acute phase of SIV infection in both
pathogenic and non-pathogenic hosts. However, the IFN-I
induction is controlled during nonpathogenic persistent SIV
infection, while the pathogenic SIV infection is featured by
sustained IFN-I production during chronic infection, correlated
with immune activation and AIDS development [17,22,23] [16].
Plasmacytoid dendritic cells (pDC) are the major IFN-I
producing cells [24]. They preferentially express TLR7 and
TLR9 in the endosome, sensing viral RNA and DNA respectively
during infection. Upon viral infections and other stimulations,
pDCs produce large amount of IFN-I and inflammatory cytokines.
However, it is still not clear if pDCs are the major source of IFN-I
during acute or chronic HIV-1 infection [25], and the role of pDC
in HIV-1 replication or disease progression is not well defined.
HIV-1 infection can stimulate pDCs to express TNF-Related
Apoptosis-Inducing Ligand (TRAIL) [26,27,28]. However, the
induction of CD4+ T-cell death by TRAIL expressing pDC
remains controversial [29]. On the other hand, pDC are also
reported to be decreased and functionally impaired in peripheral
blood of HIV-1 infected individuals [30,31,32,33]. The decline of
IFN-I producing capability of pDC is correlated with opportunistic
infection but not CD4 T-cell counts [31,34,35]. These reports
highlight that pDC may play important but complex roles in HIV-
1 infection and immunopathogenesis.
Humanized mice transplanted with human immune tissues or
cells have been developed to study HIV-1 infection [36]. In the
recent improved humanized mouse models, HIV-1 infection can
be established by inoculating through intraperitoneal [37,38],
intravenous [39], or mucosal routes [38,40]. HIV-1 infection
results in persistent viral replication, CD4 depletion in peripheral
blood and lymphoid organs. Importantly, HIV-1 infection results
in T cell depletion, correlated with immune activation in lymphoid
organs of humanized mice [41].
We and other groups have reported that functional human pDC
are developed in lymphoid tissues in humanized mouse models
[41,42,43]. Human pDC are rapidly activated by HIV-1 infection
[41] and the level of pDC activation is reversely correlated with
CD4+ T-cell numbers [41], which is consistent with the
observation from HIV-1 infected patients [15,20,21] and SIV
infected monkeys [16,23]. To define the role of human pDC in
HIV-1 replication and immunopathogenesis in vivo, we developed
a monoclonal antibody that specifically and efficiently depletes
human pDC in all lymphoid organs in humanized mice in vivo.
Thus we were able to characterize the role of human pDC in
HIV-1 infection and immunopathogenesis during acute and
chronic phases of HIV-1 infection.
Results
HIV-1 infection, immune activation and HIV-1 disease
progression in humanized mice
We have previously reported that human pDC are rapidly
activated by HIV-1 infection [41] in humanized mice and the level
of pDC activation is correlated with CD4+ T-cell depletion [41].
The pathogenic CCR5/CXCR4 dual-tropic HIV-R3A strain
efficiently established infection in humanized mice (Figure 1A),
associated with IFN-I induction and ISG expression
(Figure 1B&C), increased HLA-DR+CD38+ CD8 T cells
(Figure 1D), and CD4 T-cell depletion (Figure 1E). As in HIV-1
infected human patients, a decrease of total number of human
leukocytes was induced by HIV-1 infection in humanized mice, as
measured by cell numbers of human CD4, CD8 T cells and total
CD45+ leukocytes in lymphoid organs (Figure 1F). As shown with
chronic infection with JRCSF below, similar IFN-I induction,
immune activation and depletion of human immune cells were
observed in humanized mice (Figure S1A–E). We have reported
that pDC frequency did not change during acute HIV-R3A
infection [41]. During persistent JR-CSF infection, pDC percent-
age was also not significantly altered (data not shown). Thus, the
humanized mouse model provides a relevant in vivo model for
studying the role of pDC in HIV-1 infection and immunopatho-
genesis.
Specific depletion of human pDC with a pDC-reactive
monoclonal antibody
In order to delineate the role of human pDC in HIV-1 infection
and pathogenesis in vivo, we developed and screened a number of
pDC-reactive monoclonal antibodies (mAb) and identified an anti-
BDCA2 (CD303) mAb (15B), which could specifically deplete
human pDC in lymphoid organs in humanized mice. After 15B
injection, pDC were specifically depleted in both peripheral blood
(Figure 2A) and lymphoid organs (Figure 2B). Importantly, human
T, B, myeloid dendritic cells and monocytes\macrophages were
not perturbed by 15B mAb (Figure 2C–E and Figure S2&S3).
Depletion of pDC prior to HIV-1 infection abolishes IFN-I
induction and increases HIV-1 replication
To test the role of pDC in early acute HIV-1 infection, we
injected 15B and isotype control antibody into humanized mice on
-5, -3 and -1 days before infection, and then infected them with
HIV-R3A (a highly pathogenic dual-tropic HIV-1 strain, [44,45])
on day 0. The infected mice were treated with 15B or control
antibody two more times on 3 and 6 days post-infection (dpi). We
found that pDC remained depleted in blood and lymphoid organs
of the infected mice (Figure 3A), when terminated on 8 dpi.
Interestingly, the induction of plasma IFN-I was completely
blocked by pDC depletion in HIV-1 infected mice (Figure 3B).
The suppressed expression of different subtypes of human IFN-I
Author Summary
Persistent expression of IFN-I is correlated with disease
progression in HIV-1 infected humans or SIV-infected
monkeys. Thus, persistent pDC activation has been
implicated in contributing to AIDS pathogenesis. To define
the role of pDC in HIV-1 infection and immunopathogen-
esis in vivo, we developed a monoclonal antibody that
specifically and efficiently depletes human pDC in all
lymphoid organs in humanized mice. We discover that
pDC are the critical IFN-I producer cells in response to
acute HIV-1 infection, because depletion of pDC com-
pletely abolished induction of IFN-I or ISG by HIV-1
infection, correlated with elevated level of HIV-1 replica-
tion. When pDC were depleted during chronic HIV-1
infection in humanized mice, pDC were still the major IFN-I
producing cells in vivo, which contributed to HIV-1
suppression. Despite of higher level of viral replication in
pDC-depleted mice, we found that HIV-induced depletion
of human T cells and leukocytes was significantly reduced
in lymphoid organs, correlated with reduced cell death
induction by HIV-1 infection. Our findings demonstrate
that pDC play two opposing roles in HIV-1 pathogenesis:
they produce IFN-I to suppress HIV-1 replication and
induce death of human immune cells to contribute to HIV-
induced T cell depletion and immunopathogenesis.
Role of pDC in HIV-1 Replication and Immunopathogenesis
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was also confirmed at RNA level by real time PCR (Figure 3C). In
addition, the up-regulation of ISGs such as Mx1 and TRIM22 was
also blocked (Figure 3D and data not shown). We confirmed
similar blocking of IFN-I induction by pDC-depletion prior to
infection with the CCR5-tropic JRCSF HIV-1 strain (data not
shown). These data demonstrate that pDC are the critical IFN-I
producing cells during early HIV-1 infection in humanized mice in
vivo.
Consistent with the antiviral activity of IFN-I, HIV-1
replication reached higher levels in pDC-depleted mice in vivo
(Figure 4). The average plasma viral load was increased about
10-fold comparing with mice treated with isotype control
antibody (Figure 4A, p,0.01). We repeated the pDC depletion
experiment with the CCR5 tropic HIV-1 JR-CSF. Similar to
HIV-R3A infection, JR-CSF replication was increased in pDC-
depleted mice (about 5-fold, Figure 4B). The increase of viral
replication was further confirmed in the spleen by immunohis-
tochemistry (Figure 4C) or flow cytometry (Figure 4D&E) of
HIV p24 protein positive cells. Therefore, pDC are the critical
IFN-I producer cells in response to acute HIV-1 infection, and
they are required to significantly inhibit early HIV-1 replication.
The expression of HLA-DR and CD38 was increased in mice
with pDC depletion (Figure S4), correlated with increased level
of HIV-1 replication. These data suggest that the elevated level
of HIV-1 replication in the absence of pDC can lead to
upregulation of T-cell activation markers.
Depletion of pDC reduces HIV-induced death of human
CD4-negative leukocytes during acute HIV-R3A infection
As shown in Figure 1, HIV-R3A infection leads to rapid
immunopathogenesis including depletion of human total
leukocytes and CD8 T cells, as well as CD4 T cells. Despite
the increased HIV-R3A viral replication in pDC-depleted
mice, the absolute numbers of human CD4+ T cells in blood
and spleen were comparable to those of control mice
(Figure 5A). More surprisingly, CD8+ T cells as well as total
human CD45+ leukocytes were partly preserved in blood and
spleen in pDC-depleted mice (Figure 5B&C). Consistently, this
is correlated with decreased levels of cell death of CD45 or
CD8 T cells (Figure 5D&E). The similar cell death induction of
CD4 T cells in both groups of mice may be due to the
highly fusogenic activity of the HIV-R3A Env [45,46]. The
elevated HIV-R3A replication in pDC-depleted mice, com-
bined with its highly pathogenic direct killing activity, may
contribute to the observed CD4 T cell death induction and
depletion.
Figure 1. HIV-1 replication and pathogenesis in HIV-1-infected humanized mice. HIV-R3A replication and pathogenesis in humanized mice
are summarized. (A) Plasma viral load of mice intravenously inoculated with 1 ng p24/mouse of R3A (n = 10). Viral RNA copy numbers were measured
using real-time PCR quantification. (B) The production of IFN-a2 in plasma from uninfected (n = 3) and infected (n = 3) humanized mice measured by
Luminex. (C) The relative level of Mx1 and TRIM22 gene expression in huCD45+ cell in spleen (n = 3) detected by real time PCR. (D) Summary data of
the percentages of HLA-DR+CD38+ on CD8 T cells (CD3+CD42CD8+) in peripheral blood and spleen measured by FACS. (E) Summary data of the
percentages of CD4+ T cells of CD3+ cells. (F) Comparison of absolute CD4 T-cell, CD8 T-cell and huCD45+ cell numbers in spleen from uninfected
controls (n = 3) and R3A-infected mice (n = 10). (B–F) Mice were analyzed at 8 days post infection. All bars in dot graphs indicate median value. Error
bars indicate standard deviations (SD). * and ** indicate p,0.05 and p,0.01, respectively.
doi:10.1371/journal.ppat.1004291.g001
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PLOS Pathogens | www.plospathogens.org 3 July 2014 | Volume 10 | Issue 7 | e1004291
pDC remain as important IFN-I producer cells and inhibit
viral replication during chronic HIV-1 infection in
humanized mice
During early phase of JR-CSF infection, the decrease of CD4+
T cells and other human leukocytes was not significant (Figure S1).
To define the role of pDC in HIV-1 replication and immuno-
pathogenesis during chronic HIV-1 infection, we performed pDC
depletion during chronic HIV-JRCSF infection. Humanized mice
were infected with JR-CSF for 11 weeks, and then 15B was
applied to deplete pDC for additional 10 weeks. In agreement with
the data from acute infection, we observed a significant increase in
plasma viremia (Figure 6A). The percentage of HIV-1 infected
cells (HIV-1 p24 positive) was also significantly increased
(Figure 6B&C). Interestingly, plasma IFN-a2 decreased signifi-
cantly in the pDC-depleted mice (by 70%, Figure 6D). The
mRNA induction of different IFN-I subtypes (Figure 6E) and ISGs
(Figure 6F) in human leukocytes in spleens was almost completely
suppressed by real-time PCR and cDNA array (Figure S5). Thus,
pDC are still a major source of IFN-I, and contribute to
suppressing HIV-1 chronic infection in humanized mice.
Contribution of pDC to HIV-1 induced human leukocyte
depletion in lymphoid organs during chronic infection
In spite of the persistently higher viremia during 10 weeks of
pDC depletion treatment, human CD4+ T cell numbers
increased significantly in the spleen, comparing to the control
group (Figure 7A, p,0.05). In addition, human CD8 T cells
and CD45+ leukocyte numbers in spleens were also increased
(Figure 7B&C, p,0.01). Interestingly, the relative depletion of
human CD4, CD8 T cells and CD45 leukocytes was the same
in the blood (Figure 7A–C). The increase of human CD45+
cells in the spleen was also confirmed by immunohistochem-
istry staining of spleen sections (Figure 7D). Accordingly, pDC
depletion significantly reduced the percentage of dying cells in
T cells and total human CD45+ cells in the spleen and other
lymphoid organs (Figure 7E&F and data not shown). There-
fore, persistent activation of pDC in lymphoid organs during
HIV-1 chronic infection, although still producing IFN-I to
suppress HIV-1 replication, contributes significantly to HIV-1
induced depletion of human leukocytes including human CD4
T cells.
Figure 2. Specific depletion of human pDC in lymphoid organs in vivo with a human pDC-reactive monoclonal antibody. Humanized
Mice were treated with either 15B or isotype control (iso) antibody for 3 times on days -5, -3, -1 prior to termination. Percentages of pDC
(Lin2CD4+CD123+) in total human leukocytes (CD45+) are analyzed. (A) Representative FACS plots and summarized data show relative pDC
frequencies before and after antibody treatment in the peripheral blood (n = 7). (B) Representative FACS plots and summarized data show pDC
depletion by 15B in mesenteric lymph nodes (mLN) and spleen (SP, isotype n = 4; 15B n = 5). All bars in dot graphs indicate median value. Error bars
indicate standard deviations (SD). * and ** indicate p,0.05 and p,0.01, respectively. (C) Summarized percentages of CD32CD19+ B cells in different
lymphoid tissues. (D) Summarized percentages of CD3+CD192 T cells in different lymphoid tissues. (E) Summarized percentages of CD32CD11c+
mDC cells in different lymphoid tissues. All bars in dot graphs indicate median value.
doi:10.1371/journal.ppat.1004291.g002
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Discussion
HIV-1 infection induces a systemic immune activation [1,47],
which has been proposed to contribute to HIV-1 disease
progression [1,3,4,47,48,49]. Persistent activation of pDC and
IFN-I have been correlated with HIV-1 infection induced
immune activation both in HIV-infected patients and in SIV-
infected rhesus monkeys [15,20,21],[16,18,23,49,50,51]. The
role of pDC in HIV-1 infection and immunopathogenesis,
however, remains unclear [52,53,54]. Using the humanized
mouse model of HIV-1 infection and pathogenesis in vivo, we
developed a novel pDC-specific mAb that specifically and
efficiently depletes human pDC in various lymphoid organs in
vivo. We report here that, in response to acute HIV-1 infection,
pDC are the critical IFN-I producer cells and contribute to
suppressing HIV-1 replication during early HIV-1 infection.
During chronic HIV-1 infection, pDC are still the major IFN-I
producing cells and contribute to controlling HIV-1 replication.
Most surprisingly, depletion of pDC during chronic HIV-1
infection rescued human leukocytes including human CD4 T
cells in lymphoid organs but not in blood, in spite of higher
levels of HIV-1 replication. We conclude that pDC play two
opposing roles during HIV-1 infection and pathogenesis: they
produce IFN-I to inhibit HIV-1 replication, but enhance HIV-1
pathogenesis by promoting cell death of human leukocytes
including human CD4 and CD8 T cells.
Study of human pDC has been hampered by the difficulty of
isolating sufficient number of human pDC cells and our inability
to culture or expand pDC in vitro. Using humanized mice, we
screened a number of human pDC-specific mAb and identified the
15B mAb that specifically and efficiently depletes human pDC in
all lymphoid organs in vivo. With this mAb, we were able to define
the role of pDC in HIV-1 replication and immunopathogenesis
during different phases of HIV-1 infection. Our findings show that
Figure 3. Pre-infection depletion of pDC abolishes IFN-I induction during acute HIV-1 infection in humanized mice. (A) Summarized
data of pDC percentages in total human leukocytes (CD45+) from humanized mice are shown mice. Mice were treated with either 15B or isotype
control (iso) antibody. After pDC depletion, mice were infected with HIV-R3A and terminated on 8 days post infection (dpi) for analysis. Mock infected
mice, n = 6; isotype+R3A infected mice, n = 9; 15B+R3A infected mice, n = 12. (B) Plasma levels of IFN-a2 from mock, HIV-1 infected and 15B or isotype
mAb treated mice were quantified by Luminex assays. Mock, n = 3; isotype+R3A, n = 5; 15B+R3A, n = 5. (C) The mRNA expression of major type I IFN
genes in purified human cells (CD45+) from mouse spleens was measured by real-time PCR. (D) ISGs (Mx1 and TRIM22) expression in purified human
cells (CD45+) from mouse spleens was measured by real-time PCR. Mock, n = 3; isotype+R3A, n = 5; 15B+R3A, n = 5. Mice were analyzed at 8 days post
infection. Error bars in graphs indicate median value. Error bars indicate standard deviations (SD). * and ** indicate p,0.05 and p,0.01, respectively.
doi:10.1371/journal.ppat.1004291.g003
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pDC are the critical or only IFN-I producer cells in response to
acute HIV-1 infection in humanized mice. The pDC-independent
production of IFN-a in plasma and ISG expression after pDC
depletion during chronic HIV-1 infection may be due to the
contribution of other cell types such as mDC and macrophages
[55]. A recent report showed that TLR7 and TLR9 blockade had
minimal impact on plasma IFN-a and expression of ISG in SIV-
infected monkeys and did not alter viral load and T cell activation
in vivo [56]. The discrepancy may be due to an incomplete
blocking of pDC activation by the TLR7 and TLR9 antagonist in
vivo or different contribution of other IFN-I producing cells in
SIV-infected monkeys [56]. A recent report shows that pDC are
the major IFN-I producing cells during primary SIV infection but
the pDC pool is replenished by their precursors lacking IFN-I
production capacity post acute phase infection [57]. However, we
found that the depletion of pDC abolished or dramatically
reduced IFN-I production during acute or chronic HIV-1
infection, suggesting that pDC are the major IFN-I producing
cells during both acute and chronic HIV infection in humanized
mice. The 15B mAb does not bind the BDCA2 receptor on
monkey pDC (data not shown). The contribution of pDC in SIV-
infected monkeys needs to be reexamined by pDC depletion when
the appropriate depleting antibody is available.
The gut associated lymphoid tissue (GALT) is a major site of
human T-cell depletion by HIV-1 infection. It is important to
point out that the GALT in humanized mouse models are not
structurally developed, with impaired intestinal lymphoid organ
structure and human cell engulfment [58]. We thus can not
examine the effect of pDC depletion in GALT in the current
model. It will be interesting to examine the effect of pDC depletion
on SIV pathogenesis in the GALT of SIV-infected monkeys,
which recapitulates GALT pathogenesis as in HIV-infected
humans.
HIV-1 disease progression is associated with gradual depletion
of human leukocytes including other lineages as well as CD4 T
cells [59,60,61]. Multiple mechanisms have been reported to
account for the pathogenic activity of HIV-1 infection. Besides
direct killing of HIV-1 infected CD4 cells, bystander cells
including hematopoietic progenitor cells and uninfected human
mature cells are also depleted, associated with immune hyper-
activation during pathogenic HIV-1 infection. Several recent
reports suggest that pDC may contribute to HIV-1 induced
immune activation and subsequent immunopathogenesis. Repeat-
ed administrations of TLR7 ligands in mice induce AIDS-like
lymphopenia, with reduced CD4+ T cells, CD8+ T cells and B cells
[8]. It is reported that IFN-I triggers proapoptotic and antipro-
liferative effect on T cells [62].
We found that pDC-depletion not only rescued CD4 T cells but
also CD8 T cells and total CD45+ leukocytes in lymphoid organs
such as spleen and LN, but not in the blood. Therefore, persistent
activation of pDC by HIV-1 infection in lymphoid organs
contributes to HIV-1 immunopathogenesis by accelerating the
death of all human leukocyte cells. Similarly, recent findings
showed that treating SIV-infected rhesus macaques with the
TLR7 and TLR9 antagonist DV056 led to a significant increase in
levels of proliferating memory CD4 and CD8 T cells in the blood
[56]. Interestingly, the anti-malaria drug chloroquine, which
inhibits IFN-I production by pDC in vitro [63], appears to rescue
Figure 4. Pre-depletion of pDC leads to higher levels of HIV-1 replication. (A) Plasma HIV-1 RNA levels from HIV-R3A infected mice (genome
copy#6log10/ml) are summarized. isotype+R3A, n = 9; 15B+R3A, n = 12. (B) Plasma HIV-1 RNA levels from JR-CSF infected mice at 2 wpi are
summarized. isotype+JR-CSF, n = 12; 15B+JR-CSF, n = 12. (C) Immunohistochemistry staining for p24 positive cells in the spleen of mock or HIV-R3A
infected mice. (D) Representative FACS plots for p24 positive CD4 T cells in the spleen of mock or JRCSF infected mice at 3 wpi. (E) Summarized data
of D. isotype+JR-CSF, n = 7; 15B+JR-CSF, n = 7. Bars in dot graphs indicate median value. * indicates p,0.05.
doi:10.1371/journal.ppat.1004291.g004
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human T cells in HIV-1 infected patients, correlated with reduced
immune activation [10,11]. However, two recent reports with
similar chloroquine treatment failed to demonstrate the significant
beneficial effect in HIV-1 patients [64,65].
Two recent reports showed that blocking IFN-I signaling during
LCMV persistent infection could improve antiviral T cell response
and accelerate clearance of chronic LCMV infection via an IL-10-
related mechanism [66,67]. It is not clear if IFN-I also plays a
similar critical role in HIV-1 infection and immunopathogenesis.
It will be of great interest to test, when the human IFN-IR
antagonistic mAb is available, if blocking human IFN-IR can
similarly improve anti-HIV immunity and lead to better control of
HIV-1 infection in humanized mice or in SIV-infected monkeys.
However, pDC depletion in HIV-infected humanized mice
showed very distinct outcomes as blocking IFN-I signaling in
LCMV-infected mice. First, pDC depletion led to increased HIV-
1 replication, and it did not affect IL-10 expression (Li, G. and Su,
L., unpublished results). In addition, pDC depletion may remove
IFN-I and additional factors expressed by ‘‘bad’’ pDC, including
other inflammatory cytokines and cell death ligands such as
TRAIL (killer pDC, [27,28,68]). Therefore, persistent pDC
activation by HIV-1 infection contributes to HIV-1 induced
depletion of human immune cells and leads to HIV-1 disease
progression. Our findings suggest that depletion of ‘‘bad’’ pDC
transiently during HIV-1 chronic infection may provide an
effective treatment to preserve human immune cells in HIV-1
infected patients or in those HAART-treated immune non-
responder patients [69,70]. Recently, it was reported that blocking
IFN-I with a non-signaling IFNa during acute SIV infection
promoted viral replication, which is consistent with our data in the
current study. However, they also observed accelerated CD4+ T-
cell depletion and AIDS progression [71]. This may be due to the
distinct experimental systems between pDC depletion in human-
ized mice and IFN-I blocking in SIV-infected monkeys. pDC have
multiple functions beside IFN-I production, including production
of other inflammatory cytokines, direct killing of T cells through
TRAIL expression [68] and inhibition of antiviral immune
response by Treg induction [18]. Therefore, pDC depletion in
SIV-infected monkeys should be performed in future experiments




The reports followed NIH research ethics guidelines. For the
humanized mouse construction, human fetal liver were obtained
from elective or medically indicated termination of pregnancy
through a non-profit intermediary working with outpatient clinics
(Advanced Bioscience Resources, Alameda, CA). The use of the
tissue in research had no influence on the decision regarding
termination of the pregnancy. Informed consent of the maternal
donor is obtained in all cases, under regulation governing the
clinic. We were provided with no information regarding the
identity of the patients, nor is this information traceable. The
project was reviewed by the University’s Office of Human
Figure 5. Pre-depletion of pDC reduces HIV-R3A induced death of human leukocytes. (A) CD4 T cell (CD3+CD82) counts in peripheral
blood (PBL) and spleens (SP) of mock or HIV-R3A infected mice. (B) CD8 T cell (CD3+CD42CD8+) counts in PBL and SP. (C) Human CD45+ leukocyte
counts in PBL and SP. (D) Representative histograms show percentages of dead CD4 T cells, CD8 T cells and huCD45+ cells in spleens of mice infected
with mock or R3A at 8 dpi. (E) Summarized data of D. mock, n = 6; isotype+R3A, n = 9; 15B+R3A, n = 12. Bars in all graphs indicate median value. * and
** indicate p,0.05 and p,0.01, respectively.
doi:10.1371/journal.ppat.1004291.g005
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Research Ethics, which has determined that this submission does
not constitute human subjects research as defined under federal
regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)]
and does not require IRB approval. The University of North
Carolina at Chapel Hill Institutional Animal Care and Use
Committee (IACUC) has reviewed and approved this research. All
animal experiments were conducted following NIH guidelines for
housing and care of laboratory animals and in accordance with
The University of North Carolina at Chapel Hill in accordance
with protocols approved by the institution’s Institutional Animal
Care and Use Committee (IACUC ID: 11-103.0).
Construction of humanized mice
Approval for animal work was obtained from the University
of North Carolina Institutional Animal Care and Use Commit-
tee (IACUC). We constructed Balb/C rag2-gammaC (DKO)
mutant DKO-hu HSC or Nod-rag1-gammaC (NRG) NRG-hu
HSC mice similarly as previously reported [39]. Briefly, human
CD34+ cells were isolated from 16- to 20-week-old fetal liver
tissues. Tissues were digested with Liver Digest Medium
(Invitrogen, Frederick, MD). The suspension was filtered
through a 70 mm cell strainer (BD Falcon, Lincoln Park, NJ)
and was centrifuged at 150 g for 5 minutes to isolate mononu-
clear cells by Ficoll. After selection with the CD34+ magnetic-
activated cell sorting (MACS) kit, CD34+ HSCs (0.5 x 106) were
injected into the liver of each 2- to 6-days old DKO or NRG
mice, which had been previously irradiated at 300 rad. More
than 95% of the humanized mice were stably reconstituted with
human leukocytes in the blood (10%–90% at 12–14 weeks).
Each cohort (Humanized mice reconstituted from the same
human donor fetal liver tissue) had similar levels of engraftment.
All mice were housed at the University of North Carolina at
Chapel Hill.
HIV-1 virus stocks and infection of humanized mice
NL4-R3A, generated by cloning a highly pathogenic dual tropic
envelope into NL4-3 backbone [44,45,46], was used for acute
infection experiment. An R5 tropic strain of HIV-1, JR-CSF, was
used for both acute and chronic infection. All viruses were
generated by transfection of 293T cells. Humanized mice with
stable human leukocyte reconstitution were infected with NL4-
R3A (5 ng p24/mouse) or JR-CSF (10 ng p24/mouse), through
intravenous injection (i.v.). Humanized mice infected with 293T
mock supernatant were used as control groups.
Depletion of human pDC in humanized mice
A monoclonal antibody specific to blood dendritic cell antigen-2
(BDCA2), 15B, was used to treat humanized mice through
intraperitoneal injection (i.p., 4 mg/kg). For acute HIV-1 infec-
tion, humanized mice were injected three times with 15B on -5, -3
Figure 6. Depletion of pDC during chronic HIV-1 infection increases HIV-1 replication associated with reduced IFN-I expression.
Humanized mice were infected HIV-JRCSF and were treated weekly with 15B or control at 11 weeks post-infection and terminated at 21 weeks post-
infection (mock, n = 6; JR-CSF+control, n = 9; JR-CSF+15B, n = 9). (A) Plasma HIV-1 RNA levels (genome copy#6log10/ml) at each time point were
analyzed by real-time PCR. (B) Representative FACS histograms and summarized data (C) show percentages of HIV p24-positive CD4 T cells
(CD3+CD82) in the spleen. (D) The production of IFNa2 in the plasma, from mock infected (n = 4), JR-CSF+PBS (n = 5) and JR-CSF+15B (n = 5) at either
11 wpi (pre-) or 21 wpi (post-), was measured by Luminex. (E) The mRNA levels of IFN-I genes or ISGs Mx1 and TRIM22 (F) in purified human CD45+
cells from spleens (n = 5). All bars in dot graphs indicate median value. Error bars indicate standard deviations (SD). * and ** indicate p,0.05 and p,
0.01, respectively. Relative ISGs expression in human CD45+ cells or in CD8 T cells (CD3+CD42CD8+) in spleens are summarized in Figure S5.
doi:10.1371/journal.ppat.1004291.g006
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and -1 days before infection. For acute R3A infection, mice will be
treated on 3 and 6 days post-infection. For acute JR-CSF
infection, mice will be treated every three days until termination.
For chronic JR-CSF infection, 15B was applied to mice at 11wpi
by injecting twice every week for 10 weeks.
Flow cytometry
For HIV-1 gag p24 staining, cells were stained with surface
markers first, and then permeabilized with cytofix/cytoperm
buffer (BD Bioscience, cat#554714), followed by intracellular
staining. Human leukocytes (mCD452huCD45+) were analyzed
for human CD3, CD4, CD8, CD123, HLA-DR and CD38 by
CyAn FACS machine (Dako). FITC-conjugated anti–human
HLA-DR (clone:L243, cat#307604), PE-conjugated anti-human
CD38 (clone:HIT2, cat#303506), PE/Cy5-conjugated anti-hu-
man CD4 (clone:RP4-T4, cat#300510), PE/Cy7-conjugated anti-
human CD3 (clone:HIT3a, cat#300316), Pacific blue-conjugated
anti-human CD3 (clone:UCHT1, cat#300431), PE/Cy7-conju-
gated anti-human CD8 (clone:HIT8a, cat#300914), APC-conju-
gated human CD123 (clone:6H6, cat#306012) and APC/
Cy7-conjuaged anti-human CD45 (clone:H130, cat#304014)
were purchased from Biolegend; PE-conjugated anti-human
caspase-3 (clone:C92-605, cat#51-68655X) was purchased from
BD Bioscience. Pacific orange–conjugated anti–mouse CD45
(clone:HI30, cat#MHCD4530), PE/Texas red–conjugated anti–
human CD4 (clone:S3.5, cat#MHCD0417) or CD8 (clone:3B5,
cat#MHCD
0817), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit
(cat#L34957) were purchased from Invitrogen. FITC-conjugated
anti-HIV p24 (clone:FH190-1-1, cat#6604665) was purchased
from Beckman Coulter. The cells were analyzed on a CyAn ADP
(Dako).
Immunohistochemistry
Paraffin-embedded spleen sections from humanized mice were
stained with the mouse anti–human CD45 (Dako, cat#N1514) or
HIV-1 p24 antibody (Dako, cat#M0857), washed in PBS, then
incubated with Mouse-&-Rabbit-on-Rodent Double Stain Poly-
mer (BIOCARE MEDICAL, cat#RDS513H) and substrate DAB
(BIOCARE MEDICAL, cat#BDB2004 H, L, MM). Images were
Figure 7. Depletion of pDC during chronic infection reduces HIV-1 induced immunopathogenesis. Humanized mice were infected HIV-
JRCSF and were treated weekly with 15B or control at 11 weeks post-infection and terminated at 21 weeks post-infection (mock, n = 6; JR-CSF+
control, n = 9; JR-CSF+15B, n = 9). (A–C) Summarized data show relative numbers in PBL and SP of (A) CD4 T cells (CD3+CD82), (B) CD8 T cells
(CD3+CD42CD8+), and (C) human CD45+ leukocytes. (D) Immunohistochemistry staining for human CD45+ cells in spleens of mock or HIV-1 infected
mice. (E) FACS plots of cell death in human CD4+ T cells, CD8+ T cells and huCD45+ leukocytes from spleens. (F) Summary data show percentages of
cell death in CD4+ T cells, CD8+ T cells and huCD45+ leukocytes. Bars in dot graphs indicate median value. * and ** indicate p,0.05 and p,0.01,
respectively.
doi:10.1371/journal.ppat.1004291.g007
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captured using a QImaging Micropublisher 3.3 CCD digital
camera and QCapture software version 3.0 (QImaging, Surrey,
BC).
Cellular mRNA level detection
Interferon alpha-1/13 (IFNa1/13), interferon alpha-2 (IFNa2),
interferon beta (IFNb) [72], interferon gamma (IFNc) [73] and
tumor necrosis factor alpha (TNFa) [74] were detected. IFN-I
stimulated genes, MxA [75] and TRIM22 [76], were detected to
confirm pDCs depletion effect on type I IFN production. Real-
time PCR assay was performed (ABI Applied Biosystem). All
samples were tested in triplicate using the human GAPDH gene
[77] for normalization.
Statistical analysis
Data were analyzed using GraphPad Prism software version 5.0
(GraphPad software, San Diego, CA, USA). The methods used for
analysis of microarray data were described above. The data from
different infection groups of mice were compared using a 2-tailed
Mann-Whitney U test. For gene expression, mean-DCT was
calculated as the average (6 SD) of all DCT values within each
group of samples and 2-way ANOVA method was used.
Correlations were estimated with a Spearman test. All results
were considered significant when p,0.05.
Supporting Information
Figure S1 (A–E) Kinetics of HIV-JRCSF infection and immu-
nopathogenesis in humanized mice measured by quantitative real-
time PCR (n = 10, A), IFNa2 induction (B), immune activation of
human CD8 T cells (C), relative percentages of CD4 T cells in the
blood (PBL) or spleens (D), or total cell numbers of CD4, CD8 T
cells and human CD45+ leukocytes (E). (C–E) All mice were
analyzed at 18 weeks post HIV infection. Each dot represents one
mouse and ** indicate p,0.01.
(TIF)
Figure S2 Specific depletion of pDCs induced by 15B in
different lymphoid organs in humanized mice. Representative
FACS plots show percentages of CD3+CD19- T cells and CD3-
CD19+ B cells in huCD45+ cells (A) or CD3-CD11c+ mDC (B) in
the blood, mLN and spleens.
(TIF)
Figure S3 Specific depletion of pDCs induced by 15B in
different lymphoid organs in humanized mice. (A) Representative
FACS plots and summarized data (B) show percentages of CD3-
CD14+ cell in huCD45+ cells in the blood, mLN and spleens.
(TIF)
Figure S4 Relative T-cell activation in humanized mice with or
without pDC depletion. (A) pDC were depleted before HIV
infection, the percentage of HLA-DR+CD38+ of CD8 T cells in
the spleen at 8 days post-infection by R3A is summarized. (B) pDC
were depleted before HIV infection, the percentage of HLA-
DR+CD38+ of CD8 T cells in the spleen at 3 weeks post-infection
by JR-CSF is summarized. * indicates p,0.05.
(TIF)
Figure S5 Depletion of pDC during chronic HIV-1 infection
reduces type I IFN response. Humanized mice were infected with
HIV-JRCSF and treated with 15B or control at 11 weeks post-
infection and terminated at 21 weeks post-infection. Human cells
(CD45+ or CD3+ CD8+ T cells) from spleens of mock, HIV-1/
control or HIV-1/15B mice were purified by flow cytometry.
Total mRNA were isolated and used for the cDNA microarray
assay. Gene expression of a panel of ISGs relative to mock samples
in human CD45+ cells (left) and CD3+CD4-CD8+T cells (right) is
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